<difference-title>

Version actuelle en date du 26 janvier 2017 à 08:34

384, p?Dolutegravir clinical trial and ��SUVmax (percentage change in SUVmax) (R2?=?0.500, p?Talazoparib datasheet of conventional and nanotherapeutic drug delivery. Copyright ? 2014 John Wiley & Sons, Ltd. ""High choline kinase-�� (Chk-��) expression is frequently observed in cancer cells, making it a novel target for pharmacological and molecular inhibition. As inhibiting agents are delivered systemically, it is important to determine Chk-�� expression levels in endothelial cells that line both normal and tumor vasculature, CAPNS1 and the effect of Chk-�� downregulation on these cells. Here, we characterized Chk-�� expression and the effect of its downregulation in human umbilical vein endothelial cells (HUVECs) relative to MDA-MB-231 human breast cancer cells. We used small interfering RNA (siRNA) to downregulate Chk-�� expression. Basal mRNA levels of Chk-�� were approximately three-fold lower in HUVECs relative to MDA-MB-231 breast cancer cells. Consistent with the differences in Chk-�� protein levels, phosphocholine levels were approximately 10-fold lower in HUVECs relative to MDA-MB-231 cells. Transient transfection with siRNA-Chk resulted in comparable levels of mRNA and protein in MDA-MB-231 breast cancer cells and HUVECs. However, there was a significant reduction in proliferation in MDA-MB-231 cells, but not in HUVECs.